Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 2 天前评分70
正文 · 原文
Join Dr. Antonio Giordano (@antgiorda) at #ESMO26 for Proffered Paper Session 2, featuring data on the efficacy and safety of atirmociclib + fulvestrant in patients with HR+/HER2– advanced or metastaic #BreastCancer following progression on prior CDK4/6 inhibitor therapy. #MBC
🗓️Saturday, October 24
⏰ 08:30 - 10:00 CEST | 2:30 - 4:00 AM EST
📍 Alicante Auditorium, Hall 6
385 浏览 · 7 赞 · 6 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.org来源：Dana-Farber’s Breast Oncology Center · x.com